# Anixa Biosciences, Inc. (ANIX)

> Source: Nexqual · https://nexqual.com/ANIX · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Anixa Biosciences, Inc. (ANIX), nexqual.com/ANIX" · informational, not investment advice.

**Price:** USD 2.78 (+4.71% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 2.66 · day 2.63–2.79 · 52w 2.32–5.46 · market cap $96.6M · NCM

## Key facts
- Analysts: Buy (mean 1.75 on a 1–5 scale) (4 analysts), mean target USD 9.75 (range 6–14).
- Total return with dividends: 1Y -36.8% vs S&P 500 +18.1%; 5Y -36.7% vs S&P 500 +85.1%.
- Next earnings: 2026-09-09, EPS estimate USD -0.08, revenue estimate $0K.

## Analysts
Consensus Buy (mean 1.75 on a 1–5 scale), 4 analysts; mean target USD 9.75 (low 6, high 14).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-22 | HC Wainwright & Co. | Target lowered | Buy | $7 → $6 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -36.8% | -36.7% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -36.9% | -8.7% |
| Volatility (annualized) | 65.8% | 61.6% |
| Max drawdown | -55.0% (Dec 2025→Jun 2026) | -63.0% (Apr 2023→Jun 2024) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/ANIX · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt